Department of Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China.
Hum Vaccin Immunother. 2023 Aug;19(2):2254262. doi: 10.1080/21645515.2023.2254262. Epub 2023 Sep 20.
The investigation of therapeutic cancer vaccines has been ongoing for the past century. Herein, we used VOSviewer and CiteSpace to perform the first global bibliometric analysis of the literature on therapeutic cancer vaccines from 2013 to 2022 aiming to explore the current status and potential research trends. The findings revealed a consistent upward trend in both publication counts and citations. The United States emerged as the leading contributor with the highest number of published papers. Additionally, the analysis of references and keywords indicated that therapeutic cancer vaccines have long been popular topics, whereas neoantigen vaccines, mRNA vaccines, combination strategies, and vaccine delivery systems are emerging research hotspots. This bibliometric study provides a comprehensive and important overview of the current knowledge and potential developments in therapeutic cancer vaccines from 2013 to 2022, which may serve as a valuable reference for scholars interested in further exploring this promising field.
在过去的一个世纪里,人们一直在研究治疗性癌症疫苗。在这里,我们使用 VOSviewer 和 CiteSpace 对 2013 年至 2022 年治疗性癌症疫苗文献进行了首次全球文献计量学分析,旨在探索当前的现状和潜在的研究趋势。研究结果显示,出版物数量和引文数量都呈持续上升趋势。美国是发表论文数量最多的主要贡献者。此外,对参考文献和关键词的分析表明,治疗性癌症疫苗一直是热门话题,而新抗原疫苗、mRNA 疫苗、联合策略和疫苗传递系统则是新兴的研究热点。这项文献计量学研究全面而重要地概述了 2013 年至 2022 年治疗性癌症疫苗的现有知识和潜在发展,可能为有兴趣进一步探索这一充满希望领域的学者提供有价值的参考。